Pharvaris focuses on clinical development and pipeline expansion, with studies for HAE and AAE-C1INH planned.

From GlobeNewswire: 2025-01-13 06:50:00

Pharvaris has initiated a Phase 3 study, CHAPTER-3, to evaluate deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks, with topline data expected in 2026. Enrollment in RAPIDe-3, a Phase 3 study for on-demand HAE treatment, is ongoing with topline data anticipated in 2026. A study for acquired angioedema due to C1-INH deficiency (AAE-C1INH) is planned for 2025. Pharvaris is financially strong, with cash runway into 2026. The company outlined strategic priorities for 2025, focusing on clinical development and pipeline expansion. Business updates include new team members and presentations at medical congresses. Additionally, Pharvaris will participate in upcoming investor conferences.



Read more at GlobeNewswire: Pharvaris Outlines 2025 Strategic Priorities